Society of Interventional Oncology Grant Recipients
The Society of Interventional Oncology congratulates past recipients of grant awards.
SIO and Guerbet, LLC Announce Grant Recipients:
The Society of Interventional Oncology (SIO), a global organization working to advance interventional oncology worldwide, working in collaboration with Guerbet LLC, announce their 2018 transarterial Lipiodol® chemoembolization grant recipients.
The investigators and project proposals that have been awarded grants are:
F. Edward Boas
Memorial Sloan Kettering Cancer Center
Phase I Study of Transarterial Chemoembolization of Lung Metastases
Julius Chapiro
Yale University School of Medicine
Molecular Imaging of the Tumor Microenvironment and Immune Response in TACE
Terence Gade
Hospital of the University of Pennsylvania
Targeting the Metabolic Stress Response in Hepatocellular Carcinoma
Anil K. Pilla
University of Texas Health Science Center at Houston
Identify Proteomic Biomarkers for Outcome Prediction of Lipiodol® TACE Treatment
SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program:
The Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, and BTG plc (LSE: BTG), a global healthcare company focused on Interventional Medicine, announce their 2018 Interventional Oncology/Immuno-Oncology research grant recipients.
The investigators and project proposals that have been awarded grants are:
Rony Avritscher
University of Texas MD Anderson Cancer Center
Strategies to Modulate Liver Tumor Immune Microenvironment after Catheter-based Drug Delivery
Terence Gade, University of Pennsylvania
University of Pennsylvania
Characterization of the Immunobiologic Response Following Transarterial Chemoembolization of HCC
Samdeep Mouli
Northwestern University
Y90 Radioembolization Combined with Immune Checkpoint Blockade in an Animal Model of Hepatocellular
Isabel Newton
University of California, San Diego
Effects of Cryoablation on Hepatocellular Carcinoma Cancer Stem Cells and the Immune Response
Paul Thevenot
Ochsner Health System
Tumor-Induced Tolerance in Driving Embolization Resistance and Waitlist/Transplant Outcomes
